The Russian Ministry of Health has granted permission to FMBA (Federal Medical-Biological Agency) to carry out the first and second phases of clinical trials for a recombinant vaccine aimed at preventing birch pollen allergy and cross-food allergies (apple, peach, peanut, soy). The study will assess the effectiveness, safety, reactogenicity, and immunogenicity of the vaccine, as reported by the agency’s press service.
The preclinical studies of the vaccine have shown high effectiveness and safety. It did not exhibit toxic effects and did not cause damage to vital organs, even at a hundredfold excess of the dosage.
